{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:47:29Z","timestamp":1770749249536,"version":"3.50.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T00:00:00Z","timestamp":1555286400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s00520-019-04795-0","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T09:03:50Z","timestamp":1555405430000},"page":"113-122","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Febrile neutropenia-related care and associated costs in elderly patients with breast cancer, lung cancer, or non-Hodgkin lymphoma"],"prefix":"10.1007","volume":"28","author":[{"given":"Shuling","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiannong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Bowers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamer A. F. S.","family":"Garawin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark E.","family":"Bensink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David B.","family":"Chandler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,15]]},"reference":[{"key":"4795_CR1","doi-asserted-by":"publisher","first-page":"4524","DOI":"10.1200\/JCO.2003.05.002","volume":"21","author":"GH Lyman","year":"2003","unstructured":"Lyman GH, Dale DC, Crawford J (2003) Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 21:4524\u20134531","journal-title":"J Clin Oncol"},{"key":"4795_CR2","doi-asserted-by":"publisher","first-page":"4302","DOI":"10.1200\/JCO.2004.03.213","volume":"22","author":"GH Lyman","year":"2004","unstructured":"Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI (2004) Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin\u2019s lymphoma: a nationwide study. J Clin Oncol 22:4302\u20134311","journal-title":"J Clin Oncol"},{"key":"4795_CR3","doi-asserted-by":"publisher","first-page":"99","DOI":"10.6004\/jnccn.2009.0009","volume":"7","author":"GH Lyman","year":"2009","unstructured":"Lyman GH (2009) Impact of chemotherapy dose intensity on cancer patient outcomes. J Natl Compr Cancer Netw 7:99\u2013108","journal-title":"J Natl Compr Cancer Netw"},{"key":"4795_CR4","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1002\/cncr.22939","volume":"110","author":"M Shayne","year":"2007","unstructured":"Shayne M, Culakova E, Poniewierski MS, Wolff D, Dale DC, Crawford J, Lyman GH (2007) Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy. Cancer 110:1611\u20131620","journal-title":"Cancer"},{"key":"4795_CR5","doi-asserted-by":"publisher","first-page":"5319","DOI":"10.1002\/cncr.24560","volume":"115","author":"M Shayne","year":"2009","unstructured":"Shayne M, Culakova E, Wolff D, Poniewierski MS, Dale DC, Crawford J, Lyman GH (2009) Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy. Cancer 115:5319\u20135328","journal-title":"Cancer"},{"key":"4795_CR6","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1002\/cncr.21847","volume":"106","author":"NM Kuderer","year":"2006","unstructured":"Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106:2258\u20132266","journal-title":"Cancer"},{"key":"4795_CR7","doi-asserted-by":"publisher","first-page":"5555","DOI":"10.1002\/cncr.25332","volume":"116","author":"GH Lyman","year":"2010","unstructured":"Lyman GH, Michels SL, Reynolds MW, Barron R, Tomic KS, Yu J (2010) Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer 116:5555\u20135563","journal-title":"Cancer"},{"key":"4795_CR8","doi-asserted-by":"publisher","first-page":"859","DOI":"10.3892\/etm.2011.312","volume":"2","author":"MB Schilling","year":"2011","unstructured":"Schilling MB, Parks C, Deeter RG (2011) Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: a retrospective study. Exp Ther Med 2:859\u2013866","journal-title":"Exp Ther Med"},{"key":"4795_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3816\/SCT.2003.n.002","volume":"1","author":"GH Lyman","year":"2003","unstructured":"Lyman GH, Kuderer NM (2003) Epidemiology of febrile neutropenia. Support Cancer Ther 1:23\u201335","journal-title":"Support Cancer Ther"},{"key":"4795_CR10","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1002\/cncr.25691","volume":"117","author":"GH Lyman","year":"2011","unstructured":"Lyman GH, Kuderer NM, Crawford J, Wolff DA, Culakova E, Poniewierski MS, Dale DC (2011) Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer 117:1917\u20131927","journal-title":"Cancer"},{"key":"4795_CR11","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.critrevonc.2013.12.006","volume":"90","author":"GH Lyman","year":"2014","unstructured":"Lyman GH, Abella E, Pettengell R (2014) Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review. Crit Rev Oncol Hematol 90:190\u2013199","journal-title":"Crit Rev Oncol Hematol"},{"key":"4795_CR12","doi-asserted-by":"publisher","first-page":"720","DOI":"10.3111\/13696998.2013.782034","volume":"16","author":"B Dulisse","year":"2013","unstructured":"Dulisse B, Li X, Gayle JA, Barron RL, Ernst FR, Rothman KJ, Legg JC, Kaye JA (2013) A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia. J Med Econ 16:720\u2013735","journal-title":"J Med Econ"},{"key":"4795_CR13","doi-asserted-by":"publisher","first-page":"809","DOI":"10.2165\/11592980-000000000-00000","volume":"30","author":"SL Michels","year":"2012","unstructured":"Michels SL, Barron RL, Reynolds MW, Smoyer Tomic K, Yu J, Lyman GH (2012) Costs associated with febrile neutropenia in the US. Pharmacoeconomics 30:809\u2013823","journal-title":"Pharmacoeconomics"},{"key":"4795_CR14","unstructured":"United States Department of Labor Website. CPI Inflation Calculator. Bureau of Labor Statistics. Available at: \nhttps:\/\/www.bls.gov\/data\/inflation_calculator.htm\n\n. Accessed 22 Feb 2019"},{"key":"4795_CR15","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae). Myeloid growth factors. V1.2018. Available at: \nhttp:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloid_growth.pdf\n\n. Accessed 22 Feb 2019"},{"key":"4795_CR16","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","volume":"47","author":"MS Aapro","year":"2011","unstructured":"Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C, EOfR, Cancer To (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47:8\u201332","journal-title":"Eur J Cancer"},{"issue":"Suppl 5","key":"4795_CR17","doi-asserted-by":"publisher","first-page":"v252","DOI":"10.1093\/annonc\/mdq196","volume":"21","author":"J Naurois de","year":"2010","unstructured":"de Naurois J, Novitzky-Basso I, Gill MJ, Marti FM, Cullen MH, Roila F, Group EGW (2010) Management of febrile neutropenia: ESMO clinical practice guidelines. Ann Oncol 21(Suppl 5):v252\u2013v256","journal-title":"Ann Oncol"},{"key":"4795_CR18","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1200\/JOP.2015.006742","volume":"11","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, Bohlke K, Armitage JO (2015) Recommendations for the use of white blood cell growth factors: American Society of Clinical Oncology clinical practice guideline update. J Oncol Pract 11:511\u2013513","journal-title":"J Oncol Pract"},{"key":"4795_CR19","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines\u00ae). Older adult oncology. Version 1.2018. Available at: \nhttp:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/senior.pdf\n\n. Accessed 22 Feb 2019"},{"key":"4795_CR20","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3816\/CLM.2001.n.011","volume":"2","author":"VA Morrison","year":"2001","unstructured":"Morrison VA, Picozzi V, Scott S, Pohlman B, Dickman E, Lee M, Lawless G, Kerr R, Caggiano V, Delgado D, Fridman M, Ford J, Carter WB, Group OPPSW (2001) The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin\u2019s lymphoma receiving initial CHOP chemotherapy: a risk factor analysis. Clin Lymphoma 2:47\u201356","journal-title":"Clin Lymphoma"},{"key":"4795_CR21","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.ygyno.2012.03.015","volume":"125","author":"RA Laskey","year":"2012","unstructured":"Laskey RA, Poniewierski MS, Lopez MA, Hanna RK, Secord AA, Gehrig PA, Lyman GH, Havrilesky LJ (2012) Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer. Gynecol Oncol 125:625\u2013630","journal-title":"Gynecol Oncol"},{"key":"4795_CR22","doi-asserted-by":"publisher","first-page":"4377","DOI":"10.1007\/s00520-016-3277-0","volume":"24","author":"Y Li","year":"2016","unstructured":"Li Y, Klippel Z, Shih X, Reiner M, Wang H, Page JH (2016) Relationship between severity and duration of chemotherapy-induced neutropenia and risk of infection among patients with nonmyeloid malignancies. Support Care Cancer 24:4377\u20134383","journal-title":"Support Care Cancer"},{"key":"4795_CR23","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1634\/theoncologist.10-6-427","volume":"10","author":"GH Lyman","year":"2005","unstructured":"Lyman GH, Lyman CH, Agboola O (2005) Risk models for predicting chemotherapy-induced neutropenia. Oncologist 10:427\u2013437","journal-title":"Oncologist"},{"key":"4795_CR24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1200\/JOP.18.00269","volume":"15","author":"AJ Zimmer","year":"2019","unstructured":"Zimmer AJ, Freifeld AG (2019) Optimal management of neutropenic fever in patients with cancer. J Oncol Pract 15:19\u201324","journal-title":"J Oncol Pract"},{"key":"4795_CR25","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00520-016-3421-x","volume":"25","author":"D Weycker","year":"2017","unstructured":"Weycker D, Li X, Tzivelekis S, Atwood M, Garcia J, Li Y, Reiner M, Lyman GH (2017) Burden of chemotherapy-induced febrile neutropenia hospitalizations in US clinical practice, by use and patterns of prophylaxis with colony-stimulating factor. Support Care Cancer 25:439\u2013447","journal-title":"Support Care Cancer"},{"key":"4795_CR26","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae). Myeloid growth factors. 2015. Available at: \nhttp:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloid_growth.pdf\n\n. Accessed 22 Feb 2019"},{"key":"4795_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-13-60","volume":"13","author":"D Weycker","year":"2013","unstructured":"Weycker D, Sofrygin O, Seefeld K, Deeter RG, Legg J, Edelsberg J (2013) Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases. BMC Health Serv Res 13:60","journal-title":"BMC Health Serv Res"},{"key":"4795_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/03007995.2018.1495621","volume":"34","author":"D Weycker","year":"2018","unstructured":"Weycker D, Hanau A, Lonshteyn A, Bowers C, Garawin T, Bensink M, Chandler D (2018) Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis: a retrospective evaluation using Medicare claims. Curr Med Res Opin 34:1\u20136","journal-title":"Curr Med Res Opin"},{"key":"4795_CR29","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1007\/s00520-015-3039-4","volume":"24","author":"D Weycker","year":"2016","unstructured":"Weycker D, Li X, Barron R, Li Y, Reiner M, Kartashov A, Figueredo J, Tzivelekis S, Garcia J (2016) Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice. Support Care Cancer 24:2481\u20132490","journal-title":"Support Care Cancer"},{"key":"4795_CR30","unstructured":"Centers for Medicare & Medicaid Services. \nCMS.gov\n\n. Market Basket Data. Actual regulation market basket change and Medicare payment updates as published in the \u201cFederal Register\u201d. Available at: \nhttp:\/\/www.cms.gov\/Research-Statistics-Data-and-Systems\/Statistics-Trends-and-Reports\/MedicareProgramRatesStats\/MarketBasketData.html\n\n. Accessed 22 Feb 2019"},{"key":"4795_CR31","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.7314\/APJCP.2013.14.2.1115","volume":"14","author":"J Chindaprasirt","year":"2013","unstructured":"Chindaprasirt J, Wanitpongpun C, Limpawattana P, Thepsuthammarat K, Sripakdee W, Sookprasert A, Wirasorn K (2013) Mortality, length of stay, and cost associated with hospitalized adult cancer patients with febrile neutropenia. Asian Pac J Cancer Prev 14:1115\u20131119","journal-title":"Asian Pac J Cancer Prev"},{"key":"4795_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-14-434","volume":"14","author":"XJ Wang","year":"2014","unstructured":"Wang XJ, Wong M, Hsu LY, Chan A (2014) Costs associated with febrile neutropenia in solid tumor and lymphoma patients - an observational study in Singapore. BMC Health Serv Res 14:434","journal-title":"BMC Health Serv Res"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-019-04795-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-019-04795-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-019-04795-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,13]],"date-time":"2020-04-13T23:14:49Z","timestamp":1586819689000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-019-04795-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,15]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["4795"],"URL":"https:\/\/doi.org\/10.1007\/s00520-019-04795-0","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,15]]},"assertion":[{"value":"29 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Shuling Li and Jiannong Liu are employees of Chronic Disease Research Group, Hennepin Healthcare Research Institute, which has received project funding from Amgen, Inc. Charles Bowers, Tamer A. F. S. Garawin, Christopher Kim, Mark E. Bensink, and David B. Chandler are employees of and own stock in Amgen, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Formal consent was not required as the article does not contain any studies involving human participants performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}